NEWS
APPLE ANNOUNCES CLINICAL-GRADE HEARING AID FEATURES FOR AIRPODS PRO 2
Apple has announced an innovative , over-the-counter Hearing Aid capability for users with mild to moderate hearing loss . Using the personalised hearing profile from the Hearing Test , this new feature seamlessly transforms AirPods Pro into a clinical-grade hearing aid .
After setup , the feature enables personalised dynamic adjustments so users have the sounds around them boosted in real time . This helps users better engage in conversation and keeps them connected to the people and environment around them . With the incredible audio quality of AirPods Pro , the user ’ s personalised hearing profile is automatically applied to music , movies , games and phone calls across their devices without needing to adjust any settings .
This first-of-its-kind software-based Hearing Aid feature brings users the ability to fine-tune their experience at any time , making access to hearing assistance easier than ever at an approachable price point . Users can also set up the Hearing Aid feature with an audiogram created by a hearing health professional . Both the Hearing Test and Hearing Aid features are grounded in science and were validated through rigorous scientific studies . The Hearing Test and Hearing Aid features are expected to receive marketing authorisation from global health authorities soon and will be available this fall in more than 100 countries and regions , including the United States , Germany and Japan .
Approximately 1.5 billion people around the world are living with hearing loss , according to the World Health Organization . Building on years of work in hearing health – including the Noise app on Apple Watch , headphone audio levels with iPhone , hearing accessibility features , and the Apple Hearing Study – Apple is introducing an end-to-end experience focused on prevention , awareness and assistance .
TEMPUS ENTERS REAL WORLD DATA COLLABORATION WITH BIONTECH
Tempus AI , a technology company leading the adoption of AI to advance precision medicine and patient care , has announced a multi-year collaboration with BioNTech SE a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases . This collaboration leverages Tempus ’ robust multimodal datasets in support of BioNTech ’ s nextgeneration oncology pipeline .
Under this collaboration , Tempus is providing analytical support and computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline . BioNTech will work collaboratively with Tempus to leverage Tempus ’ real-world multimodal database to generate novel insights into the biological mechanisms supporting the discovery of new therapies and aiming to enhance the development of BioNTech ’ s clinical oncology pipeline .
“ We are looking forward to collaborating with BioNTech to combine our realworld multimodal data and cutting-edge computational technology to help advance their differentiated oncology pipeline ,” said Ryan Fukushima , Chief Operating Officer of Tempus . “ By applying Tempus ’ extensive real-world multimodal data to BioNTech ’ s AI capabilities and multi-platform discovery engine , we believe we can generate a real impact by working to bring novel therapies to those cancer patients who could potentially benefit the most .” �
12 www . intelligenthealth . tech